SCHEMBL30229149

SCHEMBL30229149

CSc1nc(SC)c(C#N)c(-c2ccco2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.55
KMT2A Q03164 9/20 0.55
KDM4E B2RXH2 8/20 0.55
MEN1 O00255 8/20 0.55
HPGD P15428 8/20 0.55
HSD17B10 Q99714 7/20 0.55
POLB P06746 5/20 0.55
TSHR P16473 3/20 0.55
USP2 O75604 2/20 0.55
MAPT P10636 4/20 0.55
NPSR1 Q6W5P4 3/20 0.55
BLM P54132 3/20 0.55
ALOX15 P16050 2/20 0.55
PTPN7 P35236 2/20 0.55
RECQL P46063 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
GAPDH P04406 1/20 0.55
NR4A1 P22736 1/20 0.55
HTT P42858 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7149747 0.86 ALDH1A1 (0.55) ALDH1A1KMT2AKDM4EMEN1HPGD
SCHEMBL6441106 0.85 ADORA2A (0.64) ALDH1A1KMT2AKDM4EMEN1HPGD
SCHEMBL1176355 0.85 ALDH1A1 (0.54) ALDH1A1KMT2AKDM4EMEN1HPGD
SCHEMBL1176202 0.85 KMT2A (0.58) ALDH1A1KMT2AKDM4EMEN1HPGD
SCHEMBL24747412 0.76 ADORA2A (0.55) ALDH1A1KMT2AKDM4EMEN1HPGD
SCHEMBL6440535 0.75 ADORA2A (0.51) ALDH1A1KMT2AKDM4EMEN1HPGD
SCHEMBL6441030 0.74 KDM4E (0.75) ALDH1A1KMT2AKDM4EMEN1HPGD
SCHEMBL6441186 0.73 ALDH1A1 (0.62) ALDH1A1KMT2AKDM4EMEN1HPGD
SCHEMBL6442942 0.72 ADORA1 (0.43) ALDH1A1KMT2AKDM4EMEN1HPGD
SCHEMBL6262120 0.71 MEN1 (1.00) ALDH1A1KMT2AKDM4EMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066864-A1 METHODS FOR IDENTIFYING ADAR1 INHIBITORS, AND COMPOSITIONS AND METHODS OF USE IN TREATING CANCER WISTAR INST (US) 2025-02-27 US disclosed
WO-2023004342-A9 METHODS FOR IDENTIFYING ADAR1 INHIBITORS, AND COMPOSITIONS AND METHODS OF USE IN TREATING CANCER THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2023-04-27 WO disclosed
WO-2023004342-A2 METHODS FOR IDENTIFYING ADAR1 INHIBITORS, AND COMPOSITIONS AND METHODS OF USE IN TREATING CANCER THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066864-A1 METHODS FOR IDENTIFYING ADAR1 INHIBITORS, AND COMPOSITIONS AND METHODS OF USE IN TREATING CANCER ADA, ADAR, NTPCR ALDH1A1 141/4885KMT2A 1122/4885KDM4E 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.